What is CRISPR Therapeutics AG Quarterly Revenue?

CRISPR Therapeutics AG Quarterly Revenue CRISPR Therapeutics AG Jun-2026 Quarterly Revenue is $10 Million which is growth of 0% YoY.

What is CRISPR Therapeutics AG Quarterly Net Profit?

CRISPR Therapeutics AG Quarterly Net Profit CRISPR Therapeutics AG Jun-2026 Quarterly Net Profit is $-91 Million which is growth of 56.3% YoY.

What is CRISPR Therapeutics AG Annual Revenue?

CRISPR Therapeutics AG Annual Revenue CRISPR Therapeutics AG Annual Revenue is $0 Million which is growth of -100.0% YoY.

What is CRISPR Therapeutics AG Annual Net Profit?

CRISPR Therapeutics AG Annual Net Profit CRISPR Therapeutics AG Annual Net Profit is $-582 Million which is growth of -58.8% YoY.

What is CRISPR Therapeutics AG Total Shareholders Fund?

CRISPR Therapeutics AG Total Shareholders Fund CRISPR Therapeutics AG Dec-2025 Total Shareholders Fund is $1,922 Million which is growth of -0.5% YoY.

What is CRISPR Therapeutics AG Total Assets?

CRISPR Therapeutics AG Total Assets CRISPR Therapeutics AG Dec-2025 Total Assets is $2,265 Million which is growth of 1.0% YoY.

What is CRISPR Therapeutics AG Book Value Per Share?

CRISPR Therapeutics AG Book Value Per Share CRISPR Therapeutics AG Book Value Per Share is $20 which is growth of -11.1% YoY.

What is CRISPR Therapeutics AG ROE?

CRISPR Therapeutics AG ROE CRISPR Therapeutics AG ROE is 0% which is growth of 0% YoY.

What is CRISPR Therapeutics AG Cash From Operating Activity?

CRISPR Therapeutics AG Cash From Operating Activity CRISPR Therapeutics AG Cash From Operating Activity is $-345 Million which is growth of -141.7% YoY.

What is CRISPR Therapeutics AG Net Cash Flow?

CRISPR Therapeutics AG Net Cash Flow CRISPR Therapeutics AG Net Cash Flow is $49 Million which is growth of 153.9% YoY.

CRISPR Therapeutics AG

XNAS: CRSP

Download real time

2.95(5.85%)

31.55% Fall from 52W High

1.5M

XNAS Volume

XNAS 09 Oct, 2026 5:30 PM (EDT)

Portfolio

Alert

My Notes

CRISPR Therapeutics AG quarterly and annual earnings report: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents

View Charts

CRISPR Therapeutics AG quarterly results: revenue, profit, and P&L – 13 quarter history

Nested row level

Base Level

Reporting Type

Originally Reported

Cell Data

Actual

Table Settings

YoY & New to Old

Nested row level

Base Level

Export

NEUTRAL
Quarterly Revenue CRISPR Therapeutics AG Jun-2026 Quarterly Revenue is $10 Million which is growth of 0% YoY.
POSITIVE
Quarterly Net Profit CRISPR Therapeutics AG Jun-2026 Quarterly Net Profit is $-91 Million which is growth of 56.3% YoY.

CRISPR Therapeutics AG, Earnings Report - Quarterly Results, standalone, All financials are in USD Million and price data in USD
Indicator	Jun '26	Mar '26	Dec '25	Sep '25	Jun '25	Mar '25	Dec '24	Sep '24	Jun '24	Mar '24	Dec '23	Sep '23	Jun '23
SR_Q Operating Rev.	10	1					35				200		70
CostOfRevenue_Q Cost Of Rev.	40.3	46	53.7	57.1	45.2	57.5		11.2	52.1	47	20	23.4	44.6
GrossProfit_Q Gross Profit	-30.3	-45	-53.7	-57.1	-45.2	-57.5	35	-11.2	-52.1	-47	180	-23.4	25.4
OEXPNS_Q Operating Exp. ⌄	87	85.3	101.1	74.9	184.2	90.9	99.6	99	99.1	93.6	110.4	109	120.6
AdminAndSellingExpenses_Q Admin Plus Selling Exp.	17.6	17.2	18.4	16.9	18.9	19.3	18.1	17.4	19.5	18	16.5	18.3	19
ResearchAndDevlopmentExpenses_Q RnD Exp.	69.6	68.6	83.5	58.9	166.2	72.5	82.2	82.2	80.2	76.2	95.1	90.7	101.6
OP_Q Operating Profit	-117.3	-130.3	-154.8	-132.1	-229.3	-148.4	-64.6	-110.1	-151.3	-140.6	69.6	-132.4	-95.2
NetNonOperIntIncExp_Q Net Non Operations Interest Incuding Expenses ⌄	-	-	-	-	-	-	-	-	-	-	-	-	-
Others_Q Other Interest Earned	-	-	-	-	-	-	-	-	-	-	-	-	-
IntExpNonOperating_Q Interest Exp. Non Operating	-	-	-	-	-	-	-	-	-	-	-	-	-
PBT_Q Profit Before Tax	-90.2	-122.1	-130	-105.8	-207.3	-134.9	-36.6	-85.1	-125.1	-115.9	89.6	-111.7	-76.8
TAX_Q Tax	1	0.8	0.6	0.6	1.3	1.1	0.7	0.9	1.3	0.7	0.2	0.4	0.9
NICommonStockholders_Q Net Income Common Stockholders ⌄	-91.2	-122.9	-130.6	-106.4	-208.6	-136	-37.3	-85.9	-126.4	-116.6	89.4	-112.2	-77.7
NP_Q Net Profit	-91.2	-122.9	-130.6	-106.4	-208.6	-136	-37.3	-85.9	-126.4	-116.6	89.4	-112.2	-77.7
NIIncludingNoncontrollingInterests_Q Net Income Including Non controlling Interests	-91.2	-122.9	-130.6	-106.4	-208.6	-136	-37.3	-85.9	-126.4	-116.6	89.4	-112.2	-77.7
DilutedNIAvailtoComStockholders_Q Diluted NI Avail to Com Stockholders Ann.	-91.2	-122.9	-130.6	-106.4	-208.6	-136	-37.3	-85.9	-126.4	-116.6	89.4	-112.2	-77.7
EPS_Q Basic EPS	-0.9	-1.3	-1.4	-1.2	-2.4	-1.6	-0.4	-1	-1.5	-1.4	1.1	-1.4	-1
AfterDilutedEPS_Q Diluted EPS After ExtraOrdinary	-0.9	-1.3	-1.4	-1.2	-2.4	-1.6	-0.4	-1	-1.5	-1.4	1.1	-1.4	-1
SHARE_Q Number Of Shares End	96.5	96.1	95.3	91.3	87.1	85.9	85.5	85.2	84.9	81.8	79.7	79.4	79.1
NIContinuingDiscontinuedOper_Q Net Income Continuing Discontinued Operations	-91.2	-122.9	-130.6	-106.4	-208.6	-136	-37.3	-85.9	-126.4	-116.6	89.4	-112.2	-77.7
NormalizedIncome_Q Normalized Income	-75.3	-108	-114.1	-91.3	-192.4	-117.5	-17.2	-66.2	-104.8	-98.8	107.7	-93.9	-57.8
InterestIncome_Q Interest Income	-	-	-	-	-	-	-	-	-	-	-	-	-
INT_Q Interest	-	-	-	-	-	-	-	-	-	-	-	-	-
NetInterestIncome_Q Net Interest Income	-	-	-	-	-	-	-	-	-	-	-	-	-
EBIT_Q EBIT	-90.2	-122.1	-130	-105.8	-207.3	-134.9	-36.6	-85.1	-125.1	-115.9	89.6	-111.7	-76.8
EBITDA_Q EBITDA	-85.9	-117.8	-124.3	-101.4	-202.6	-130.2	-31.8	-80.3	-120.3	-111	94.5	-111.7	-71.8
ReconciledCostOfRevenue_Q Reconciled Cost Of Rev.	40.3	46	53.7	57.1	45.2	57.5		11.2	52.1	47	20	23.4	44.6
ReconciledDepreciation_Q Reconciled Depr.	4.3	4.3	5.7	4.4	4.7	4.7	4.8	4.7	4.8	4.8	4.9	4.9	5
ProfitLossFromContinuingOperations_Q Profit From Continuing Operations	-91.2	-122.9	-130.6	-106.4	-208.6	-136	-37.3	-85.9	-126.4	-116.6	89.4	-112.2	-77.7
NormalizedEBITDA_Q Normalized EBITDA	-113	-125.9	-149.1	-127.6	-224.7	-143.7	-59.8	-105.4	-146.4	-135.8	74.5	-127.5	-90.3

*All financials are in USD Million and price data in USD

Add metric to table

Search...

CRISPR Therapeutics AG competitor comparison and performance snapshot within industry

CRISPR Therapeutics AG annual results: revenue, profit, P&L, and margins as of Dec 2025 – 11 year history

Nested row level

Base Level

Reporting Type

Originally Reported

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

NEGATIVE
Annual Revenue CRISPR Therapeutics AG Annual Revenue is $0 Million which is growth of -100.0% YoY.
NEGATIVE
Annual Net Profit CRISPR Therapeutics AG Annual Net Profit is $-582 Million which is growth of -58.8% YoY.

CRISPR Therapeutics AG, Earnings Report - Annual Results, standalone, All financials are in USD Million and price data in USD
Indicator	CAGR 3 Yrs	CAGR 5 Yrs	TTM	Dec '25	Dec '24	Dec '23	Dec '22	Dec '21	Dec '20	Dec '19	Dec '18	Dec '17	Dec '16	Dec '15
SR_A Total Rev. Ann. ⌄	-66.3%	-34.5%			35	370	0.4	913.1	0.5	289.6	3.1	41	5.2	0.3
TotalOperatingRevenues_A Operating Rev. Ann.	-66.3%	-34.5%	11		35	370	0.4	913.1	0.5	289.6	3.1	41	5.2	0.3
CostOfRevenue_A Cost Of Rev. Ann.	24.6%	-	197	213.5	110.3	130.3	110.3	-	-	-	-	-	-	-
GrossProfit_A Gross Profit Ann.	-	-	-186	-213.5	-75.3	239.8	-109.8	-	-	-	-	-	-	-
OEXPNS_A Operating Exp. Ann.	-7.1%	4.9%	348.3	451.1	391.3	462.3	563.4	539.6	355	242.9	162.1	105.6	73.3	26
OP_A Operating Profit Ann.	-	-	-534.3	-664.6	-466.6	-222.5	-673.2	373.5	-354.4	46.7	-158.9	-64.7	-68.1	-25.7
NetNonOperIntIncExp_A Net Non Operations Interest Incuding Expenses Ann, ⌄	-	-		-	-	-	-	-	-	-		-	-8.1	-0.1
Others_A Other Interest Earned Ann.	-	-		-	-	-	-	-	-	-	-	-	-	-
IntExpNonOperating_A Interest Exp. Non Operating Ann.	-	-		-	-	-	-	-	-	-		-	8.1	0.1
OtherExpenses_A Other Exp. Ann.	56.3%	68.4%		86.6	103.9	71.8	22.7	6	6.4	20.6	-5.5	-2	53.5	0
PBT_A PBT Ann.	-	-	-448.1	-578	-362.7	-150.7	-650.5	379.5	-348.1	67.3	-164.4	-66.6	-22.7	-25.8
TAX_A Tax Ann.	-	35.1%	3	3.6	3.6	2.9	-0.3	1.9	0.8	0.5	0.6	1.8	0.5	0
NICommonStockholders_A Net Income Common Stockholders Ann. ⌄	-	-	-451.1	-581.6	-366.3	-153.6	-650.2	377.7	-348.9	66.9	-165	-68.4	-23.2	-25.8
NP_A Net Profit Ann.	-	-	-451.1	-581.6	-366.3	-153.6	-650.2	377.7	-348.9	66.9	-165	-68.4	-23.2	-25.8
NIIncludingNoncontrollingInterests_A Net Income Including Non controlling Interests Ann.	-	-	-451.1	-581.6	-366.3	-153.6	-650.2	377.7	-348.9	66.9	-165	-68.4	-23.2	-25.8
DilutedNIAvailtoComStockholders_A Diluted NI Avail to Com Stockholders Ann.	-	-	-451.1	-581.6	-366.3	-153.6	-650.2	377.7	-348.9	66.9	-165	-68.4	-23.2	-25.8
EPS_A EPS Ann.	-	-		-6.5	-4.3	-1.9	-8.4	5	-5.3	1.2	-3.4	-1.7	-1.9	-1.3
DilutedEPS_A Diluted EPS Ann.	-	-		-6.5	-4.3	-1.9	-8.4	4.7	-5.3	1.2	-3.4	-1.7	-1.9	-1.3
SHARE_Q Number Of Shares End	6.8%	6%		95.3	85.5	79.7	78.3	76.7	71.3	67.6	51.7	40.5	39.7	29.3
TotalExpenses_A Total Exp. Ann.	-0.4%	13.4%		664.6	501.6	592.5	673.6	539.6	355	242.9	162.1	105.6	73.3	26
NIContinuingDiscontinuedOper_A Net Income Continuing Discontinued Operations Ann.	-	-	-451.1	-581.6	-366.3	-153.6	-650.2	377.7	-348.9	66.9	-165	-68.4	-23.2	-25.8
NormalizedIncome_A Normalized Income Ann.	-	-	-388.6	-515.3	-287	-79.5	-552.3	479.5	-292.6	94.7	-136.3	-52.9	-23.7	-22.8
InterestIncome_A Interest Income Ann.	-	-		-	-	-	-	-	-	-	-	-	-	-
INT_A Interest Ann.	-	-		-	-	-	-	-	-	-		-	8.1	0.1
EBITDA_A EBITDA Ann.	-	-	-429.4	-558.5	-343.4	-130.9	-626.3	397.5	-338.9	72	-160.9	-63.6	-13.7	-25.6
ReconciledCostOfRevenue_A Reconciled Cost Of Rev. Ann.	24.6%	-	197	213.5	110.3	130.3	110.3	-	-	-	-	-	-	-
ReconciledDepreciation_A Reconciled Depr. Ann.	-6.9%	16.2%	18.7	19.5	19.3	19.8	24.2	18	9.2	4.7	3.5	3	0.9	0.1
ProfitLossFromContinuingOperations_A Profit From Continuing Operations Ann.	-	-	-451.1	-581.6	-366.3	-153.6	-650.2	377.7	-348.9	66.9	-165	-68.4	-23.2	-25.8
NormalizedEBITDA_A Normalized EBITDA Ann.	-	-	-515.6	-645.1	-447.3	-202.7	-649	391.5	-345.3	51.5	-160.9	-61.6	-25.2	-25.6

*All financials are in USD Million and price data in USD

Add metric to table

Search...

Total Rev. Ann.

1Y CHG

-90.5%

2Y CAGR

835.4%

3Y CAGR

-66.3%

5Y CAGR

-34.5%

7Y CAGR

-2.2%

Operating Exp. Ann.

1Y CHG

15.3%

2Y CAGR

-1.2%

3Y CAGR

-7.1%

5Y CAGR

4.9%

7Y CAGR

15.7%

10Y CAGR

33%

Operating Expenses Annual Cr growth is stable compared to historical averages.

CRISPR Therapeutics AG balance sheet as of Dec 2025: assets, liabilities, reserves, and borrowings – 11 year history

Nested row level

Base Level

Reporting Type

Originally Reported

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

NEGATIVE
Total Shareholders Fund CRISPR Therapeutics AG Dec-2025 Total Shareholders Fund is $1,922 Million which is growth of -0.5% YoY.
POSITIVE
Total Assets CRISPR Therapeutics AG Dec-2025 Total Assets is $2,265 Million which is growth of 1.0% YoY.

CRISPR Therapeutics AG, Balance Sheet, standalone, All financials are in USD Million and price data in USD
Indicator	CAGR 3 Yrs	CAGR 5 Yrs	Dec '25	Dec '24	Dec '23	Dec '22	Dec '21	Dec '20	Dec '19	Dec '18	Dec '17	Dec '16	Dec '15
TA_A Total Assets Ann. ⌄	0.3%	4.4%	2,265.2	2,242	2,229.6	2,243.1	2,751.9	1,828	1,066.8	489	271.4	345	159.4
CA_A Total Current Assets Ann.	2.3%	3%	1,985.7	1,937.1	1,908.1	1,853	2,417.5	1,716.6	987.6	466.4	248.4	320.2	156.8
CashEquivalentsShortTermInvestments_A Cash Equivalents and Short Term Investments Ann.	2.9%	3.2%	1,975.8	1,903.8	1,693.7	1,815.3	2,379.1	1,690.3	943.8	456.7	239.8	315.5	156
Receivables_A Change In Account Receivables Ann.	336.8%	201.7%		25	200		0.3	0.1	0.1	0.1	2.6	3.2	0.3
Inventories_A Inventories Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
OtherCurrentAssets_A Other Current Assets Ann.	-36.2%	-	9.8	8.3	14.4	37.7	-	-	-	-	-	-	-
TotalNonCurrentAssets_A Total Non Current Assets Ann.	-10.5%	20.2%	279.6	304.9	321.5	390	334.4	111.4	79.2	22.6	23	24.8	2.6
NetPPE_A Net PPE Ann.	-8.3%	21.6%	247.6	277.6	305.9	320.6	312	93	72.8	18.5	18.9	21	1.3
InvestmentsAndAdvances_A Investments & Advances Ann.	-	-	-		2	53.1	-	-	-	-	-	-	-
OtherNonCurrentAssets_A Other Non Current Assets Ann.	25.2%	12.1%	32	27.4	13.6	16.3	22.2	18.1	6.1	3.8	3.8	3.4	0.8
TotalLiabilitiesNetMinorityInterest_A Total Liabilities Net Minority Interest Ann. ⌄	-2.2%	16%	343.4	310	346.8	367.6	352.4	163.7	127.3	96.8	83.5	112.1	188.6
CL_A Total Current Liabilities Ann.	7.2%	9.6%	149.1	87.8	108.8	121.1	119.9	94.3	57.1	27.8	14.5	22	10.2
PayablesAndAccruedExpenses_A Payables & Accrued Exp.s Ann.	-1.2%	6.7%	101.7	56.2	83.9	105.3	106.5	73.4	36.7	26.3	13.4	20.9	10.1
CurrentDebtCapLeaseObligation_A Current Debt Cap Lease Obligation Ann.	5.6%	10.3%	18.6	17.3	15.6	15.8	12.2	11.4	8.5	-	-	-	-
CurrentDeferredLiabilities_Q Current Deferred Liabilities	-	47%	15.8	3.9	4.1		1	2.3	1	1.2	1	1	-
OtherCurrentLiabilities_A Other Current Liabilities Ann.	-	12.7%	13.1	10.4	5.1	0	0.2	7.2	11	0.2	0.1	0.1	0.1
TotalNonCurrentLiabilities_A Total Non Current Liabilities Ann.	-7.6%	22.8%	194.3	222.2	238	246.5	232.5	69.5	70.2	69.1	69	90.1	178.4
LongTermDebtAndCapitalLeaseObligation_Q LT Debt & Capital Lease Obligation	-6.2%	30.3%	188.2	206.4	223	228.2	212.9	50.1	44.1	-	-	-	38.3
TradeandOtherPayablesNonCurrent_A Trade & Other Payables Non Current Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
TotalDeferredCreditsAndOtherNonCurrentLiabilities_A Total Deferred Credits & Other Non Current Liabilities Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
TotalShareHoldersFunds_A Total ShareHolders Funds Ann. ⌄	0.8%	2.9%	1,921.8	1,932.1	1,882.8	1,875.5	2,399.5	1,664.2	939.4	392.2	187.8	232.9	-29.1
EQCAP_A Equity Share Capital Ann.	0.8%	2.9%	1,921.8	1,932.1	1,882.8	1,875.5	2,399.5	1,664.2	939.4	392.2	187.8	232.9	-29.1
CapitalStock_A Capital Stock Ann.	8.9%	6.2%	3.1	2.7	2.5	2.4	2.4	2.3	1.9	1.6	1.2	1.2	0.2
RetainedEarnings_A Retained Earnings Ann.	-	-	-1,947.6	-1,366	-999.7	-846.1	-195.9	-573.6	-224.7	-291.6	-125.4	-57.1	-33.9
GainsLossesNotAffectingRetainedEarnings_A Gains Losses Not Affecting Retained Earnings Ann.	-	-	4.8	1.8	1.9	-15.7	-5.1	-0.1	0	-0	0	-0	-0
TotalCapitalization_A Total Capitalization Ann.	0.8%	2.9%	1,921.8	1,932.1	1,882.8	1,875.5	2,399.5	1,664.2	939.4	392.2	187.8	232.9	9.2
TangibleAssets_A Tangible Assets Ann.	0.8%	2.9%	1,921.8	1,932.1	1,882.8	1,875.4	2,399.3	1,664.1	939.2	391.9	187.5	232.5	-29.6
WC_A Working Capital Ann.	2%	2.5%	1,836.6	1,849.4	1,799.3	1,731.9	2,297.6	1,622.4	930.4	438.7	233.9	298.2	146.7
InvestedCapital_A Invested Capital Ann.	0.8%	2.9%	1,921.8	1,932.1	1,882.8	1,875.5	2,399.5	1,664.2	939.4	392.2	187.8	232.9	9.2
TangibleBookValue_A Tangible Book Value Ann.	0.8%	2.9%	1,921.8	1,932.1	1,882.8	1,875.4	2,399.3	1,664.1	939.2	391.9	187.5	232.5	-29.6
Borrowings_A Borrowings Ann.	-5.4%	27.5%	206.8	223.7	238.6	244	225	61.4	52.5	-	-	-	38.3
NetDebt_A Net Debt Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
ShareIssued_A Share Issued Ann.	6.8%	5.3%	96	85.9	80.2	78.7	77.2	74.1	61	52.2	41	40.2	39.8
SHARE_Q Number Of Shares End	6.8%	6%	95.3	85.5	79.7	78.3	76.7	71.3	67.6	51.7	40.5	39.7	29.3

*All financials are in USD Million and price data in USD

Add metric to table

Search...

Total Assets Ann.

1Y CHG

2Y CAGR

0.8%

3Y CAGR

0.3%

5Y CAGR

4.4%

7Y CAGR

24.5%

10Y CAGR

30.4%

Total Assets Annual growth is stable compared to historical averages.

Total Current Liabilities Ann.

1Y CHG

69.8%

2Y CAGR

17.1%

3Y CAGR

7.2%

5Y CAGR

9.6%

7Y CAGR

27.1%

10Y CAGR

30.8%

Total Current Liabilities Annual Cr growth is higher than historical averages.

Total ShareHolders Funds Ann.

1Y CHG

-0.5%

2Y CAGR

3Y CAGR

0.8%

5Y CAGR

2.9%

7Y CAGR

25.5%

Total ShareHolders Funds Annual is falling faster than historical averages.

CRISPR Therapeutics AG ROE, ROCE, book value, and debt-to-equity ratio as of Dec 2025 – 11 year history

Nested row level

Base Level

Reporting Type

Originally Reported

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

NEGATIVE
Book Value Per Share CRISPR Therapeutics AG Book Value Per Share is $20 which is growth of -11.1% YoY.
NEUTRAL
ROE CRISPR Therapeutics AG ROE is 0% which is growth of 0% YoY.

CRISPR Therapeutics AG, Ratios, standalone, All financials are in USD Million and price data in USD
Indicator	CAGR 3 Yrs	CAGR 5 Yrs	Dec '25	Dec '24	Dec '23	Dec '22	Dec '21	Dec '20	Dec '19	Dec '18	Dec '17	Dec '16	Dec '15
ROA_A RoA Ann. %	-	-	-	-16.38%	-6.87%	-26.03%	16.49%	-24.10%	8.59%	-43.40%	-22.18%	-9.20%	-32.09%
ROE_A ROE Ann. %	-	-	-	-19.20%	-8.17%	-30.42%	18.59%	-26.80%	10.04%	-56.89%	-32.50%	-22.78%	-
ROIC_Q ROIC %	-	-	-	-1.7	4.4	-5.1	-5.3	-6.9	3.8	-11.8	0.1	20.1	-
OPMPCT_A OPM Ann. %	-	-	-	-1,333.05%	-60.15%	-154,394.72%	40.91%	-65,273.48%	16.14%	-5,087.80%	-157.69%	-1,319.33%	-10,416.60%
NBTO_A Inventory Turnover Ratio Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
ASETTO_A Asset Turnover Ann. %	-	-	-	0	0.2		0.4		0.4	0	0.1	0
WCTO_A Working Capital Turnover Ann.	-	-		0	0.2		0.4		0.3	0	0.2	0
QuickRatio_A Quick Ratio Ann.	-	-	-	22	17.4	15	19.9	17.9	16.5	16.5	16.7	14.5	15.4
CRATIO_A Current Ratio Ann.	-	-	-	22.1	17.5	15.3	20.2	18.2	17.3	16.8	17.1	14.6	15.4
IC_A Interest Coverage Ratio Ann.	-	-	-	-	-	-	-	-	-	-	-	-1.8	-238.1
LTDE_A LT Debt To Equity Ann.	-	-	-	0.1	0.1	0.1	0.1	0	0.1	-	-	-	-

*All financials are in USD Million and price data in USD

Add metric to table

Search...

CRISPR Therapeutics AG cash flow: net, operating, investing, and financing flows as of Dec 2025 – 11 year history

Nested row level

Base Level

Reporting Type

Originally Reported

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

NEGATIVE
Cash From Operating Activity CRISPR Therapeutics AG Cash From Operating Activity is $-345 Million which is growth of -141.7% YoY.
POSITIVE
Net Cash Flow CRISPR Therapeutics AG Net Cash Flow is $49 Million which is growth of 153.9% YoY.

CRISPR Therapeutics AG, Cash Flow, standalone, All financials are in USD Million and price data in USD
Indicator	CAGR 3 Yrs	CAGR 5 Yrs	Dec '25	Dec '24	Dec '23	Dec '22	Dec '21	Dec '20	Dec '19	Dec '18	Dec '17	Dec '16	Dec '15
CFO_A Cash from Operating Act. Ann. ⌄	-	-	-345	-142.8	-260.4	-495.7	539	-238.4	56.7	-96.2	-70.1	-55.3	59.4
ProfitLossFromContinuingOperations_A Profit From Continuing Operations Ann.	-	-	-581.6	-366.3	-153.6	-650.2	377.7	-348.9	66.9	-165	-68.4	-23.2	-25.8
DepreciationAmortizationDepletion_A Depreciation Amortization Depletion Ann.	-6.9%	16.2%	19.5	19.3	19.8	24.2	18	9.2	4.7	3.5	3	0.9	0.1
DepreciationAndAmortization_A Depreciation And Amortization Ann.	-6.9%	16.2%	19.5	19.3	19.8	24.2	18	9.2	4.7	3.5	3	0.9	0.1
DeferredTax_A Deferred Tax Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
DeferredIncomeTax_A Deferred Income Tax Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
EmployeesStockOptions_A ESOPs Ann.	-9.6%	1.9%	72.5	86.6	81	98	102.4	66	44.1	35	18.9	10.8	3.7
OtherNonCashItems_A Other Non Cash Items Ann.	79.8%	107.3%	72.7	-38.6	-14	12.5	-	1.9	-	15.4	-	8.1	0.1
ChangeInWorkingCapital_A Change In Working Capital Ann.	53.7%	16.6%	71.9	156.3	-193.6	19.8	26.9	33.4	-48.4	10.6	-25.4	1.8	81.4
ChangeInReceivables_A Change In Receivables Ann.	336.8%	-	25	175	-200	0.3	-0.2	-0	-0	2.5	0.5	-2.8	-0.3
ChangeInInventory_A Change In Inventory Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
ChangePayablesAccruedExpense_A Change Payables Accrued Expense Ann.	105.2%	11.7%	44.9	-27.3	-20.3	5.2	37.5	25.8	5	12.1	-0.8	3.9	7.7
ChangeInOtherCurrentAssets_A Change In Other Current Assets Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
ChangeInOtherCurrentLiabilities_A Change In Other Current Liabilities Ann.	-	-	4.3	9.6	0.1	-1.5	-5.3	-10.5	25	0.3	0.3	-0	0
ChangeInOtherWorkingCapital_A Change In Other Working Capital Ann.	-	-	-5.6	-6.4	3.3	14.3	8.7	0.9	-45.8	-1	-21.2	1.8	74.6
CFI_A Cash from Investing Act. Ann. ⌄	-	-	-31.8	-280.5	374.7	-258.7	-1,035.4	-541.2	1.3	-2.8	-8.3	31.9	-1.2
NetPPEPurchaseAndSale_A Net PPE Purchase & Sale Ann.	-	-	-0.9	-1.9	-9.5	-37.2	-81.7	-18.4	-6.7	-2.8	-7.8	-3	-1.2
PurchaseOfPPE_A Purchase Of PPE Ann.	-	-	-0.9	-1.9	-9.5	-37.2	-81.7	-18.4	-6.7	-2.8	-7.8	-3	-1.2
NetBusinessPurchaseAndSale_A Net Business Purchase & Sale Ann.	-	-	-	-	-	-	-	-	-		-	34.9	-
PurchaseOfBusiness_A Purchase Of Business Ann.	-	-	-	-	-	-	-	-	-		-	-0.1	-
PurchaseOfInvestment_A Purchase Of Investment Ann.	-	-	-1,017.9	-1,486.4	-1,065.9	-1,417.8	-1,509.3	-594			-0.5	-	-
SaleOfInvestment_A Sale Of Investment Ann.	-5.4%	70%	1,012	1,207.8	1,452.5	1,196.3	555.6	71.2	-	-	-	-	-
NetOtherInvestingChanges_A Net Other Investing Changes Ann.	-	-	-	-	-	-	-	-	8	-	-	-	-
CFA_A Cash from Financing Act. Ann. ⌄	122.6%	-16%	426	332	62.7	38.6	250.9	1,016.2	431	315.9	2.6	183.2	96.7
NetIssuancePaymentsOfDebt_A Net Issuance Payments Of Debt Ann.	-	-	-	-	-	-	-	-	-		-	35	38.2
NetLongTermDebtIssuance_A Net Long Term Debt Issuance Ann.	-	-	-	-	-	-	-	-	-		-	35	38.2
NetShortTermDebtIssuance_A Net ST Debt Issuance Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
NetCommonStockIssuance_A Net Common Stock Issuance Ann.	635.6%	-16.5%	398.1	300.7	32.7	1	213.3	982.3	415	307	-	89.1	-
CommonStockIssuance_A Common Stock Issuance Ann.	635.6%	-16.5%	398.1	300.7	32.7	1	213.3	982.3	415	307.1	-	89.1	-
CommonStockPayments_A Common Stock Payments Ann.	-	-	-	-	-	-	-			-0.1	-	-	-
dividend_1Y_actual Dividend 1year	-	-
DividendPerShare_A Dividend Per Share Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
NetOtherFinancingCharges_A Net Other Financing Charges Ann.	-	-	-	-	-	-	-	-	-	-	-	-1.8	-0.4
CashAndCashEquivalentEndOfYear_A Cash Plus Cash Eqv. End Of Year Ann.	17%	-21.2%	359.1	309.8	401.1	224.1	939.9	1,185.5	948.8	459.8	239.8	315.5	156
NetIncDecInCashAndCashEquivalents_A Net Increase In Cash Plus Cash Eqv.s Ann.	-	-27%	49.2	-91.3	176.9	-715.8	-245.5	236.6	489	216.9	-75.8	159.8	155
CashAndCashEquivalentBeginOfYear_A Cash Plus Cash Eqv. Begin Of Year Ann.	-30.9%	-20.1%	309.8	401.1	224.1	939.9	1,185.5	948.8	459.8	242.9	315.5	156	0.9
IncomeTaxPaidSupplementalData_A Income Tax Paid Supplemental Data Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
InterestPaidSupplementalData_A Interest Paid Supplemental Data Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
CapitalExpenditure_A Capex Ann.	-	-	-25.9	-1.9	-12	-37.2	-81.7	-18.4	-6.7	-2.8	-7.8	-3	-1.2
IssuanceOfCapitalStock_A Issuance Of Capital Stock Ann.	635.6%	-16.5%	398.1	300.7	32.7	1	213.3	982.3	415	307.1	-	150	58.6
IssuanceOfDebt_A Issuance Of Debt Ann.	-	-	-	-	-	-	-	-	-		-	35	38.2
RepaymentOfDebt_A Repayment Of Debt Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
RepurchaseOfCapitalStock_A Repurchase Of Capital Stock Ann.	-	-	-	-	-	-	-			-0.1	-	-	-
FreeCashFlow_A Free Cash Flow Ann.	-	-	-370.9	-144.7	-272.4	-532.9	457.3	-256.7	50	-99	-77.9	-58.3	58.3

*All financials are in USD Million and price data in USD

Add metric to table

Search...

Cash from Financing Act. Ann.

1Y CHG

28.3%

2Y CAGR

160.7%

3Y CAGR

122.6%

5Y CAGR

-16%

7Y CAGR

4.4%

10Y CAGR

16%

Cash from Financing Annual Activity growth is stable compared to historical averages.

Quarterly
Competitors/Peers
Annual
Balance Sheet
Ratios
Cash Flow

31.55% Fall from 52W High

CRISPR Therapeutics AG quarterly and annual earnings report: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents

CRISPR Therapeutics AG - Earnings Report - Quarterly Results

CRISPR Therapeutics AG quarterly results: revenue, profit, and P&L – 13 quarter history

Quarterly Revenue CRISPR Therapeutics AG Jun-2026 Quarterly Revenue is $10 Million which is growth of 0% YoY.

Quarterly Net Profit CRISPR Therapeutics AG Jun-2026 Quarterly Net Profit is $-91 Million which is growth of 56.3% YoY.

CRISPR Therapeutics AG - Competitors/Peers

CRISPR Therapeutics AG competitor comparison and performance snapshot within industry

CRISPR Therapeutics AG - Earnings Report - Annual Results

CRISPR Therapeutics AG annual results: revenue, profit, P&L, and margins as of Dec 2025 – 11 year history

Annual Revenue CRISPR Therapeutics AG Annual Revenue is $0 Million which is growth of -100.0% YoY.

Annual Net Profit CRISPR Therapeutics AG Annual Net Profit is $-582 Million which is growth of -58.8% YoY.

CRISPR Therapeutics AG - Balance Sheet

CRISPR Therapeutics AG balance sheet as of Dec 2025: assets, liabilities, reserves, and borrowings – 11 year history

Total Shareholders Fund CRISPR Therapeutics AG Dec-2025 Total Shareholders Fund is $1,922 Million which is growth of -0.5% YoY.

Total Assets CRISPR Therapeutics AG Dec-2025 Total Assets is $2,265 Million which is growth of 1.0% YoY.

CRISPR Therapeutics AG - Ratios

CRISPR Therapeutics AG ROE, ROCE, book value, and debt-to-equity ratio as of Dec 2025 – 11 year history

Book Value Per Share CRISPR Therapeutics AG Book Value Per Share is $20 which is growth of -11.1% YoY.

ROE CRISPR Therapeutics AG ROE is 0% which is growth of 0% YoY.

CRISPR Therapeutics AG - Cash Flow

CRISPR Therapeutics AG cash flow: net, operating, investing, and financing flows as of Dec 2025 – 11 year history

Cash From Operating Activity CRISPR Therapeutics AG Cash From Operating Activity is $-345 Million which is growth of -141.7% YoY.

Net Cash Flow CRISPR Therapeutics AG Net Cash Flow is $49 Million which is growth of 153.9% YoY.